Treatment of relapsed/refractory CLL with Venetoclax-Rituximab during the COVID-19 pandemic: A daily-life experience in southern Italy.

Treatment of relapsed/refractory CLL with Venetoclax-Rituximab during the COVID-19 pandemic: A daily-life experience in southern Italy.

With more than 3 million proven infections and 100.000 associated deaths in Italy, the COVID-19 pandemic poses extraordinary challenges to health-care professionals and especially to those caring for patients with haematologic malignancies  (1-2). Given the multiple   immune  defects characterizing...

Full description

Bibliographic Details
Main Authors: Stefano Molica, Paolo Sportoletti, Nicola Di Renzo, Pellegrino Musto, Fabrizio Pane, Francesco Di Raimondo
Format: Article
Language:English
Published: PAGEPress Publications 2021-06-01
Series:Mediterranean Journal of Hematology and Infectious Diseases
Subjects:
CLL, symptomatic COVID19 , Venetoclax-rituximab, time-limited therapy
Online Access:https://www.mjhid.org/index.php/mjhid/article/view/4613
id doaj-8b865993864446f6bb19eb47e1dd631c
record_format Article
spelling doaj-8b865993864446f6bb19eb47e1dd631c2021-06-29T03:06:02ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062021-06-0113110.4084/MJHID.2021.042Treatment of relapsed/refractory CLL with Venetoclax-Rituximab during the COVID-19 pandemic: A daily-life experience in southern Italy.Stefano Molica0Paolo Sportoletti1Nicola Di Renzo2Pellegrino Musto3Fabrizio Pane4Francesco Di Raimondo5smolica@libero.it2) Centro di Ricerca Emato-Oncologica (CREO), University of Perugia, Perugia, Italy3) U.O.C. Ematologia, Presidio Ospedaliero Vito Fazi, Lecce, Italy4) Unit of Hematology and Stem Cell Transplantation, AOUC Policlinico, Aldo Moro" University School of Medicine, 70124 Bari, Italy5) Department of Clinical Medicine and Surgery, Hematology Unit, Federico II University Medical School, Naples, Italy6) Division of Hematology, Department of Surgery and Medical Specialties, University of Catania, Policlinico, Italy With more than 3 million proven infections and 100.000 associated deaths in Italy, the COVID-19 pandemic poses extraordinary challenges to health-care professionals and especially to those caring for patients with haematologic malignancies  (1-2). Given the multiple   immune  defects characterizing chronic lymphocytic leukaemia (CLL), it is considered that patients with this form of leukemia have a high-risk of suffering severe forms of COVID-19 (3-4). https://www.mjhid.org/index.php/mjhid/article/view/4613CLL, symptomatic COVID19 , Venetoclax-rituximab, time-limited therapy
collection DOAJ
language English
format Article
sources DOAJ
author Stefano Molica
Paolo Sportoletti
Nicola Di Renzo
Pellegrino Musto
Fabrizio Pane
Francesco Di Raimondo
spellingShingle Stefano Molica
Paolo Sportoletti
Nicola Di Renzo
Pellegrino Musto
Fabrizio Pane
Francesco Di Raimondo
Treatment of relapsed/refractory CLL with Venetoclax-Rituximab during the COVID-19 pandemic: A daily-life experience in southern Italy.
Mediterranean Journal of Hematology and Infectious Diseases
CLL, symptomatic COVID19 , Venetoclax-rituximab, time-limited therapy
author_facet Stefano Molica
Paolo Sportoletti
Nicola Di Renzo
Pellegrino Musto
Fabrizio Pane
Francesco Di Raimondo
author_sort Stefano Molica
title Treatment of relapsed/refractory CLL with Venetoclax-Rituximab during the COVID-19 pandemic: A daily-life experience in southern Italy.
title_short Treatment of relapsed/refractory CLL with Venetoclax-Rituximab during the COVID-19 pandemic: A daily-life experience in southern Italy.
title_full Treatment of relapsed/refractory CLL with Venetoclax-Rituximab during the COVID-19 pandemic: A daily-life experience in southern Italy.
title_fullStr Treatment of relapsed/refractory CLL with Venetoclax-Rituximab during the COVID-19 pandemic: A daily-life experience in southern Italy.
title_full_unstemmed Treatment of relapsed/refractory CLL with Venetoclax-Rituximab during the COVID-19 pandemic: A daily-life experience in southern Italy.
title_sort treatment of relapsed/refractory cll with venetoclax-rituximab during the covid-19 pandemic: a daily-life experience in southern italy.
publisher PAGEPress Publications
series Mediterranean Journal of Hematology and Infectious Diseases
issn 2035-3006
publishDate 2021-06-01
description With more than 3 million proven infections and 100.000 associated deaths in Italy, the COVID-19 pandemic poses extraordinary challenges to health-care professionals and especially to those caring for patients with haematologic malignancies  (1-2). Given the multiple   immune  defects characterizing chronic lymphocytic leukaemia (CLL), it is considered that patients with this form of leukemia have a high-risk of suffering severe forms of COVID-19 (3-4).
topic CLL, symptomatic COVID19 , Venetoclax-rituximab, time-limited therapy
url https://www.mjhid.org/index.php/mjhid/article/view/4613
work_keys_str_mv AT stefanomolica treatmentofrelapsedrefractorycllwithvenetoclaxrituximabduringthecovid19pandemicadailylifeexperienceinsouthernitaly
AT paolosportoletti treatmentofrelapsedrefractorycllwithvenetoclaxrituximabduringthecovid19pandemicadailylifeexperienceinsouthernitaly
AT nicoladirenzo treatmentofrelapsedrefractorycllwithvenetoclaxrituximabduringthecovid19pandemicadailylifeexperienceinsouthernitaly
AT pellegrinomusto treatmentofrelapsedrefractorycllwithvenetoclaxrituximabduringthecovid19pandemicadailylifeexperienceinsouthernitaly
AT fabriziopane treatmentofrelapsedrefractorycllwithvenetoclaxrituximabduringthecovid19pandemicadailylifeexperienceinsouthernitaly
AT francescodiraimondo treatmentofrelapsedrefractorycllwithvenetoclaxrituximabduringthecovid19pandemicadailylifeexperienceinsouthernitaly
_version_ 1721355667939262464

Similar Items